Dimethyl sulfoxide: a central player since the dawn of cryobiology, is efficacy balanced by toxicity?

0540030 - ÚEM 2021 RIV GB eng J - Journal Article
Awan, M. - Buriak, I. - Fleck, R. - Fuller, B. - Goltsev, A. - Kerby, J. - Lowdell, M. - Měřička, P. - Petrenko, A. - Petrenko, Yuriy - Rogulska, O. - Stolzing, A. - Stacey, G.N.
Dimethyl sulfoxide: a central player since the dawn of cryobiology, is efficacy balanced by toxicity?
Regenerative Medicine. Roč. 15, č. 3 (2020), s. 1463-1491. ISSN 1746-0751. E-ISSN 1746-076X
Institutional support: RVO:68378041
Keywords : cell therapy * cell therapy safety * cryobiology
OECD category: Neurosciences (including psychophysiology
Impact factor: 3.806, year: 2020
Method of publishing: Open access
https://www.futuremedicine.com/doi/10.2217/rme-2019-0145

Dimethyl sulfoxide (DMSO) is the cryoprotectant of choice for most animal cell systems since the early history of cryopreservation. It has been used for decades in many thousands of cell transplants. These treatments would not have taken place without suitable sources of DMSO that enabled stable and safe storage of bone marrow and blood cells until needed for transfusion. Nevertheless, its effects on cell biology and apparent toxicity in patients have been an ongoing topic of debate, driving the search for less cytotoxic cryoprotectants. This review seeks to place the toxicity of DMSO in context of its effectiveness. It will also consider means of reducing its toxic effects, the alternatives to its use and their readiness for active use in clinical settings.
Permanent Link: http://hdl.handle.net/11104/0317700